Sanofi struck a partnership to license a Phase 1‑stage trispecific T‑cell engager from Kali Therapeutics, paying $180 million upfront and structuring the broader pact at up to $1.2 billion. The move marks Sanofi’s re‑entry into the T‑cell engager space and highlights large pharmas’ appetite for multispecific platforms that can redirect T‑cells to tumors. Kali’s trispecific is designed to engage T cells with improved tumor targeting; Sanofi said the asset complements its immuno‑oncology ambitions. Company statements noted the upfront and near‑term payments would support clinical expansion and translational studies in California‑based Kali. The deal underscores continued strategic interest in T‑cell engagers despite prior waves of partnership activity and varying clinical readouts across the modality.